Worth reading
38Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
21.3
Year-on-year change in revenue (%)Wording
Definitive
How definitive the wording is.Contents of this document
Financial results presentationFirst quarter of the fiscal year ending June 20274 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales43,729 Millions of yen+21.3%
Operating profit17,569 Millions of yen+34.8%
Ordinary income17,909 Millions of yen+39.0%
Net income12,706 Millions of yen+38.0%
Gross Profit Margin73.9
Operating profit margin40.2
Selling, general and administrative expenses14,737 Millions of yen
Results for the three months of the current quarter
Net Sales
43,729 Millions of yen
Operating profit
17,569 Millions of yen
Ordinary income
17,909 Millions of yen
Profit attributable to owners of parent for the quarter
12,706 Millions of yen
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Increase in revenue5,393 Millions of yen
- Increase in gross margin1,477 Millions of yen
- Increase in R&D Expenses-285 Millions of yen
- Increase in expenses other than R&D expenses-2,073 Millions of yen
- Decrease in goodwill amortization and other expenses22 Millions of yen
Key KPIsA metric the company considers important as a management benchmark.
- EPS47.89 Yen+39.3%
Segment results
- Medical BusinessNet Sales38,438 Millions of yen (YoY +21.4%)Operating profit18,553 Millions of yen (YoY +48.4%)
- Device BusinessNet Sales5,291 Millions of yen (YoY +20.6%)Operating profit1,372 Millions of yen (YoY -44.4%)
Capital expenditures
2,037 Millions of yen
| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | First quarter of the fiscal year ending June 2027 |
| Net Sales | 43,729 Millions of yen (YoY +21.3%) |
| Operating profit | 17,569 Millions of yen (YoY +34.8%) |
| Ordinary income | 17,909 Millions of yen (YoY +39.0%) |
| Net income | 12,706 Millions of yen (YoY +38.0%) |
| Gross Profit Margin | 73.9 |
| Operating profit margin | 40.2 |
| Selling, general and administrative expenses | 14,737 Millions of yen |
| Results for the three months of the current quarter | Net Sales 43,729 Millions of yen / Operating profit 17,569 Millions of yen / Ordinary income 17,909 Millions of yen / Profit attributable to owners of parent for the quarter 12,706 Millions of yen |
| Segment results | Segment Medical Business / Net Sales 38,438 Millions of yen (YoY +21.4%) / Operating profit 18,553 Millions of yen (YoY +48.4%), Segment Device Business / Net Sales 5,291 Millions of yen (YoY +20.6%) / Operating profit 1,372 Millions of yen (YoY -44.4%) |
| Breakdown of Factors Affecting the Change | Increase in revenue 5,393 Millions of yen, Increase in gross margin 1,477 Millions of yen, Increase in R&D Expenses -285 Millions of yen, Increase in expenses other than R&D expenses -2,073 Millions of yen, Decrease in goodwill amortization and other expenses 22 Millions of yen |
| Key KPIs | EPS 47.89 Yen (YoY +39.3%) |
| Capital expenditures | 2,037 Millions of yen |
Items this document does not state (17)
Full-year earnings forecastProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&ANew initiatives
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased due to expanded sales in both the medical and device businesses, as well as the boost from the weaker yen. Operating profit benefited from higher revenue and an increase in the gross profit margin. Factors contributing to the higher gross profit margin included productivity improvements, US tariff refunds, a change in the method of managing supplies, and foreign exchange effects. SG&A expenses increased due to higher sales-related expenses, personnel expenses, and research and development expenses, among others. Operating profit in the device business declined due to higher cost of sales resulting from the change in the method of managing supplies, among other factors.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.